CNBX Pharmaceuticals annual return on equity
2006
2007
2008
2009
2010
2011
2019
2020
2021
2022
CNBX Pharmaceuticals Return on Equity (ROE) Growth & History (CNBX)
CNBX Pharmaceuticals's return on equity was −216.58% for fiscal 2022.
View full CNBX Pharmaceuticals company overviewCNBX Pharmaceuticals annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2022 | 2022-08-31 | −216.58% | −37.64 pp |
| 2021 | 2021-08-31 | −178.94% | −88.47 pp |
| 2020 | 2020-08-31 | −90.47% | −103.50 pp |
| 2019 | 2019-08-31 | 13.03% | — |
| 2011 | 2011-08-31 | −1,699.29% | −1601.40 pp |
| 2010 | 2010-08-31 | −97.89% | −48.44 pp |
| 2009 | 2009-08-31 | −49.45% | −40.40 pp |
| 2008 | 2008-08-31 | −9.04% | +1.01 pp |
| 2007 | 2007-08-31 | −10.05% | +17.92 pp |
| 2006 | 2006-08-31 | −27.97% | — |
CNBX Pharmaceuticals quarterly return on equity
Q4.14
Q1.15
Q2.15
Q3.17
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q4.22
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q4 2022 | 2022-08-31 | −213.29% | −180.37 pp |
| Q2 2022 | 2022-02-28 | −1,601.85% | −1580.62 pp |
| Q1 2022 | 2021-11-30 | −101.43% | −58.08 pp |
| Q4 2021 | 2021-08-31 | −32.92% | +1.30 pp |
| Q3 2021 | 2021-05-31 | −43.30% | −17.51 pp |
| Q2 2021 | 2021-02-28 | −21.23% | −2.31 pp |
| Q1 2021 | 2020-11-30 | −43.36% | +6.07 pp |
| Q4 2020 | 2020-08-31 | −34.23% | −26.05 pp |
| Q3 2020 | 2020-05-31 | −25.79% | −22.86 pp |
| Q2 2020 | 2020-02-29 | −18.91% | −46.50 pp |
| Q1 2020 | 2019-11-30 | −49.43% | −38.23 pp |
| Q4 2019 | 2019-08-31 | −8.18% | +19.55 pp |
| Q3 2019 | 2019-05-31 | −2.94% | +26.69 pp |
| Q2 2019 | 2019-02-28 | 27.59% | +85.26 pp |
| Q1 2019 | 2018-11-30 | −11.20% | — |
| Q4 2018 | 2018-08-31 | −27.73% | — |
| Q3 2018 | 2018-05-31 | −29.63% | −11.44 pp |
| Q2 2018 | 2018-02-28 | −57.67% | — |
| Q3 2017 | 2017-05-31 | −18.19% | — |
| Q2 2015 | 2015-02-28 | −30.49% | — |
| Q1 2015 | 2014-11-30 | −56.71% | — |
| Q4 2014 | 2014-08-31 | −929.45% | — |
CNBX Pharmaceuticals return on equity trends
Between the periods ended 2006-08-31 and 2022-08-31, CNBX Pharmaceuticals's return on equity decreased from −27.97% to −216.58%, a change of −188.61 percentage points. The latest reported quarter, Q4 2022, shows −213.29%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review CNBX Pharmaceuticals source filings ↗